Skip to main content
SpringerLink
Log in

Long-Term Efficacy and Tolerability of Acarbose Treatment in Patients with Type 2 Diabetes Mellitus

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Objective:The aim of the study was to investigate the efficacy and tolerability of long-term acarbose therapy in type 2 diabetic patients.

Study design: In this double-blind, single-centre group comparison, patients were randomised to receive either acarbose or matching placebo, in addition to their regular antidiabetic therapy, over a period of 78 weeks. Eligibility for inclusion in the efficacy evaluation included a study duration of ≥510 days.

Methods: The primary efficacy parameter was the change in glycosylated haemoglobin (HbA1) from baseline to end of study. Secondary variables included changes in blood glucose and lipid parameters, as well as signs of retinopathy and nephropathy.

Patients: A total of 139 patients were assessed for safety and 88 patients (44 in each treatment group) were included in the efficacy analysis. Patients were generally overweight and the majority had previously been treated with sulphonylureas.

Results: Acarbose significantly improved fasting and 1-hour postprandial blood glucose levels compared with placebo (p = 0.039 and 0.009), and improvements in HbA1 with acarbose versus placebo fell just short of significance (p = 0.057). There were no differences between treatments in changes in microvascular complications, but blood pressure improved with acarbose treatment. Two patients in the acarbose group experienced elevated liver enzyme levels. Generally, acarbose had a good safety profile and was well tolerated.

Conclusion: Long-term treatment with acarbose was safe and efficacious in patients with type 2 diabetes mellitus that was insufficiently controlled by other oral antidiabetics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1

Similar content being viewed by others

References

  1. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999 Jun; 281(21): 2005–12

    Article  PubMed  CAS  Google Scholar 

  2. Laube H. Acarbose: an update of its therapeutic use in diabetes treatment. Clin Drug Invest 2002; 22(3): 141–56

    Article  CAS  Google Scholar 

  3. Breuer H-WM. Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes. Int J Clin Pharmacol Ther 2003; 41(10): 421–40

    PubMed  CAS  Google Scholar 

  4. Hasche H, Mertes G, Brans C, et al. Effects of acarbose treatment in type 2 diabetic patients under dietary training. A multicentre, double-blind, placebo-controlled, 2-year study. Diabetes Nutr Metab 1999; 12: 277–85

    PubMed  CAS  Google Scholar 

  5. Mertes G. Safety and efficacy of acarbose in the treatment of type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract 2001; 52: 193–204

    Article  PubMed  CAS  Google Scholar 

  6. Chiasson J-L, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002 Jun; 359: 2072–7

    Article  PubMed  CAS  Google Scholar 

  7. Chiasson J-L, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003 Jul; 290: 486–94

    Article  PubMed  CAS  Google Scholar 

  8. Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25: 10–6

    Article  PubMed  CAS  Google Scholar 

  9. Stettier C, Mueller B, Diem P. What you always wanted to know about HbA1c [in German]. Schweiz Med Wochenschr 2000; 130: 993–1005

    Google Scholar 

  10. James TM, Davis JE, McDonald JM, et al. Comparison of hemoglobin A1c and hemoglobin A1 in diabetic patients. Clin Biochem 1981; 14(1): 25–7

    Article  PubMed  Google Scholar 

  11. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 Sep; 352: 837–53

    Article  Google Scholar 

  12. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716–30

    Article  Google Scholar 

  13. Riddle M. Combining sulfonylureas and other oral agents. Am J Med 2000 Apr; 108(6A): 15S–22S

    Article  PubMed  CAS  Google Scholar 

  14. Bayraktar M, Van Thiel DH, Adalar N. A comparison of acarbose versus metformin as an adjuvant therapy in sulphonylurea-treated NIDDM patients. Diabetes Care 1996 Mar; 19: 252–4

    Article  PubMed  CAS  Google Scholar 

  15. May C. Efficacy and tolerability of stepwise increasing dosage of acarbose in patients with non-insulin-dependent diabetes mellitus (NIDDM), treated with sulfonylureas [in German]. Diabetes und Stoffwechsel 1995; 4: 3–8

    Google Scholar 

  16. Wilms B, Ruge D. Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. Diabet Med 1999; 16: 755–61

    Article  Google Scholar 

  17. Costa B, Piñol C. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes Res Clin Pract 1997; 38: 33–40

    Article  PubMed  CAS  Google Scholar 

  18. Lam KSL, Tiu SC, Tsang MW, et al. Acarbose in NIDDM patients with poor control on conventional oral agents. Diabetes Care 1998 Jul; 21: 1154–8

    Article  PubMed  CAS  Google Scholar 

  19. Lin BJ, Wu H-P, Huang HS, et al. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas. J Diabetes Complications 2003; 17: 179–85

    Article  PubMed  CAS  Google Scholar 

  20. Chiasson J-L, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med 1994; 121: 928–35

    PubMed  CAS  Google Scholar 

  21. Bachmann W, Petzinna D, Raptis SA, et al. Long-term improvement of metabolic control by acarbose in type 2 diabetes patients poorly controlled with maximum sulfonylurea therapy. Clin Drug Invest 2003; 23(10): 679–86

    Article  CAS  Google Scholar 

  22. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UKPDS 44). Diabetes Care 1999 Jun; 22: 960–4

    Article  PubMed  CAS  Google Scholar 

  23. Adler AI, Stratton IM, Neil HAW, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000 Aug; 321: 412–9

    Article  PubMed  CAS  Google Scholar 

  24. Rosenthal JH, Mauersberger H. Effects on blood pressure of the α-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Clin Drug Invest 2002; 22(10): 695–701

    Article  CAS  Google Scholar 

  25. Frantz S, Calvillo L, Tillmanns J, et al. Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the α-glucosidase inhibitor acarbose. FASEB J 2005 Apr; 19: 591–3

    PubMed  CAS  Google Scholar 

  26. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a ‘causal’ antioxidant therapy. Diabetes Care 2003 May; 26: 1589–96

    Article  PubMed  CAS  Google Scholar 

  27. Rudofsky Jr G, Reismann P, Schiekofer S, et al. Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-κB activation in PBMCs. Horm Metab Res 2004; 36: 630–8

    Article  PubMed  CAS  Google Scholar 

  28. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 Aug; 321: 405–12

    Article  PubMed  CAS  Google Scholar 

  29. Bayer HealthCare. Glucobay®. Available from URL: http://www.glucobay.com [Accessed 2004; Aug 24]

Download references

Acknowledgements

This study was supported by a research grant from Bayer AG, Germany. Dr Segal has no further conflicts of interest to report. Dieter Petzinna, Dieter Neuser, Andreas Brückner and Manfred Spengler are all employees of Bayer HealthCare AG.

Author information

Authors and Affiliations

  1. Diabetes and Lipid Metabolism Unit, Sheba Medical Center, Tel-Hashomer, and Sackler Medical School, Tel-Aviv University, Tel-Aviv, 52621, Israel

    Pesach Segal & Haskel E. Eliahou

  2. Bayer Health Care AG, Wuppertal, Germany

    Dieter Petzinna, Dieter Neuser, Andreas Brückner & Manfred Spengler

Authors
  1. Pesach Segal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haskel E. Eliahou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dieter Petzinna
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dieter Neuser
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andreas Brückner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Manfred Spengler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pesach Segal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Segal, P., Eliahou, H.E., Petzinna, D. et al. Long-Term Efficacy and Tolerability of Acarbose Treatment in Patients with Type 2 Diabetes Mellitus. Clin. Drug Investig. 25, 589–595 (2005). https://doi.org/10.2165/00044011-200525090-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200525090-00004

Keywords

Search

Navigation